Difficulty: Medium
Average Score: 73%
Practice
The intermittently multiplying (spurter) tubercle bacilli present within caseous material having low oxygen tension are most susceptible to
Correct answer
B
Rationale
In the context of chemotherapy drugs for tuberculosis, the correct answer is B) Rifampin. Rifampin is effective against intermittently multiplying (spurter) tubercle bacilli due to its unique mechanism of action, which involves inhibiting bacterial RNA synthesis. This is particularly effective against bacteria in low-oxygen conditions, such as those found within caseous material in the lungs where the tubercle bacilli reside.
Ethambutol (A) targets cell wall synthesis and is not as effective against the bacilli in low-oxygen environments. Streptomycin (C) interferes with protein synthesis and is more effective against actively multiplying bacteria rather than intermittently multiplying ones. Pyrazinamide (D) is most effective at acidic pH levels, which are not typically found in caseous material.
Understanding the susceptibility of different chemotherapy drugs to specific conditions and stages of bacterial growth is crucial in effectively treating tuberculosis. By knowing the mechanisms of action of each drug, healthcare providers can tailor treatment regimens to target the bacteria at their most vulnerable points, ultimately improving patient outcomes and reducing the development of drug resistance.
Ethambutol (A) targets cell wall synthesis and is not as effective against the bacilli in low-oxygen environments. Streptomycin (C) interferes with protein synthesis and is more effective against actively multiplying bacteria rather than intermittently multiplying ones. Pyrazinamide (D) is most effective at acidic pH levels, which are not typically found in caseous material.
Understanding the susceptibility of different chemotherapy drugs to specific conditions and stages of bacterial growth is crucial in effectively treating tuberculosis. By knowing the mechanisms of action of each drug, healthcare providers can tailor treatment regimens to target the bacteria at their most vulnerable points, ultimately improving patient outcomes and reducing the development of drug resistance.